Catalio Capital Management’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
Other funds holding BMY
Catalio Capital Management's BMY Position: Q2 2026 in Review
Catalio Capital Management reduced its Bristol-Myers Squibb (BMY) stake by 1.8% in Q2 2026, selling an estimated $446K and leaving 412,961 shares worth $23.8M. The position accounts for 4.47% of the portfolio, ranked #7.
Catalio Capital Management first reported a position in BMY in Q4 2024 and has held it in 4 quarters since. The position peaked at $34.9M in Q4 2025. 2,517 funds tracked by Wall St. Rank hold BMY as of Q2 2026.
- Catalio Capital Management held 412,961 shares of Bristol-Myers Squibb worth $23.8M as of Q2 2026.
- Catalio Capital Management sold 7,766 Bristol-Myers Squibb shares in Q2 2026, an estimated $446K.
- Bristol-Myers Squibb made up 4.47% of Catalio Capital Management's portfolio in Q2 2026, its #7 holding.
- Catalio Capital Management first reported a position in Bristol-Myers Squibb in Q4 2024 and has held it in 4 quarters since.
- Catalio Capital Management's Bristol-Myers Squibb position peaked at $34.9M in Q4 2025.
- 2,517 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.
Based on Catalio Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.